Effect of L-arginine-nitric oxide system on chemical-induced diabetes mellitus

I K Mohan1, U N Das

  • 1Division of Internal Medicine, L.V. Prasad Eye Institute, Hyderabad, India.

Insights

Nitric oxide precursor L-arginine and nitric oxide donor sodium nitroprusside protect against alloxan-induced diabetes in rats. Nitric oxide synthase inhibitor L-NMMA blocked this protective effect, indicating nitric oxide

Area of Science:

  • Biochemistry
  • Endocrinology
  • Immunology

Background:

  • In vitro studies suggest nitric oxide mediates cytokine-induced beta-cell destruction.
  • In vivo studies on nitric oxide synthase inhibitors and diabetes yield conflicting results.

Purpose of the Study:

  • To investigate the role of nitric oxide in alloxan-induced diabetes in male Wistar rats.
  • To determine the effects of L-arginine, L-NMMA, and sodium nitroprusside on alloxan-induced diabetes.

Main Methods:

  • Alloxan was used to induce diabetes in rats.
  • Rats were treated with L-arginine (nitric oxide precursor), L-NMMA (nitric oxide synthase inhibitor), or sodium nitroprusside (nitric oxide donor).
  • Biochemical parameters including plasma insulin, nitric oxide, lactate, ketone bodies, lipid peroxides, and antioxidant enzyme levels were measured.

Main Results:

  • L-arginine and sodium nitroprusside administration abrogated alloxan-induced diabetes.
  • L-NMMA blocked the protective effects of L-arginine.
  • Alloxan-induced diabetes caused metabolic and oxidative stress, which were ameliorated by insulin, L-arginine, and sodium nitroprusside treatments.

Conclusions:

  • L-arginine and nitric oxide play a protective role against alloxan-induced beta-cell damage and diabetes development.
  • Nitric oxide can restore antioxidant status in experimental diabetes.
  • These findings highlight the therapeutic potential of nitric oxide modulation in diabetes.

Related Concept Videos

Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.